Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis

被引:99
|
作者
Dhanasekaran, Renumathy [1 ]
West, Jonathan K. [1 ]
Gonzales, Patrick C. [1 ]
Subramanian, Ram [2 ]
Parekh, Samir [2 ]
Spivey, James R. [2 ]
Martin, Louis G. [1 ]
Kim, Hyun S. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiol, Div Intervent Radiol & Image Guided Med, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷 / 03期
关键词
CHILD-PUGH; MANAGEMENT; SURVIVAL; ASCITES; TIPS; MELD;
D O I
10.1038/ajg.2009.634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: We sought to study effectiveness, survival, and complications after transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis and symptomatic refractory hepatic hydrothorax. METHODS: Consecutive patients who underwent TIPS between January 1992 and December 2008 for refractory hydrothorax were reviewed retrospectively. Clinical, laboratory, and procedural data were collected for all patients by retrospective chart review. Chi-square test was used to compare categorical variables and t-test to compare continuous variables. The Kaplan-Meier method was used for survival analysis. Survival curves were compared using the log-rank test. RESULTS: Seventy-three patients were included in the study, and their mean age at TIPS creation was 55.62 years (s.d. 11.65). The mean pre- and post-TIPS portosystemic gradients were 18.9 (s.d. 4.7) mm and 5.7 (s.d. 2.4) mm Hg (P<0.001), respectively. The rates of favorable clinical response within 1 month and at 6 months after TIPS were 79% (58/73) and 75% (30/40), respectively. Median of the study group was 517 days (95% CI 11-626). The short-term survival rates at 30, 60, and 90 days were 81, 78, and 72%, respectively. The long-term survival rates at 1, 3, and 5 years were 48, 26, and 15%, respectively. Multivariate analysis by Cox proportional hazards method showed that pre-TIPS model for end-stage liver disease (MELD) score (P=0.039, HR 1.9 (95% CI 1.0-3.7)) and clinical response (P=0.003, HR 2.5 (95 % CI 1.4-4.5)) were significantly and independently associated with overall survival. The 30-day mortality rate was 19 %. Pre-TIPS creatinine levels (P=0.024, HR 3.42 (95 % CI 1.2-9.9)) were significantly associated with 30-day mortality. CONCLUSIONS: TIPS can be successfully used to achieve symptomatic relief in patients with refractory hepatic hydrothorax. Better clinical response after TIPS and pre-TIPS MELD score less than 15 were associated with longer survival after TIPS.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 50 条
  • [31] Transjugular intrahepatic portosystemic shunt in refractory chylothorax due to liver cirrhosis
    Philipp Lutz
    Holger Strunk
    Hans Heinz Schild
    Tilman Sauerbruch
    World Journal of Gastroenterology, 2013, (07) : 1140 - 1142
  • [32] Transjugular intrahepatic portosystemic shunt in refractory chylothorax due to liver cirrhosis
    Lutz, Philipp
    Strunk, Holger
    Schild, Hans Heinz
    Sauerbruch, Tilman
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (07) : 1140 - 1142
  • [33] Further experiments are necessary to determine whether transjugular intrahepatic portosystemic shunt is the definitive treatment for refractory hepatic hydrothorax
    Keiji Mitamura
    Journal of Gastroenterology, 1999, 34 : 154 - 156
  • [34] Further experiments are necessary to determine whether transjugular intrahepatic portosystemic shunt is the definitive treatment for refractory hepatic hydrothorax
    Mitamura, K
    JOURNAL OF GASTROENTEROLOGY, 1999, 34 (01) : 154 - 156
  • [35] ROLE OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) IN THE PRIMARY MANAGEMENT OF REFRACTORY CIRRHOTIC HYDROTHORAX
    STRAUSS, RM
    MARTIN, LG
    KAUFMAN, SL
    GALLOWAY, JR
    WARING, JP
    BOYER, TD
    HEPATOLOGY, 1992, 16 (04) : A85 - A85
  • [36] Treatment of refractory hydrothorax in cirrhosis with transjugular intrahepatic porto-systemic shunt
    Péron, JM
    Dupuis, E
    Alric, L
    Ottal, P
    Rousseau, H
    Barange, K
    Payen, JL
    Pascal, JP
    Vinel, JP
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1999, 23 (03): : 414 - 415
  • [37] SLEEP DISTURBANCE IN PATIENTS WITH CIRRHOSIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
    Zhao, Ming
    Luo, Xuefeng
    Wang, Xiaoze
    Yan, Yuling
    GASTROENTEROLOGY, 2024, 166 (05) : S1580 - S1580
  • [38] Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis
    Troels M. Busk
    Søren Møller
    Flemming Bendtsen
    Current Hepatology Reports, 2017, 16 (3) : 250 - 257
  • [39] Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients
    Su, An Ping
    Cao, Shuang Shuang
    Tian, Bo Le
    Zhang, Zhao Da
    Hu, Wei Ming
    Zhang, Yi
    Wang, Zheng Liang
    Babu, Shah Ram
    Hu, Tao
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (01) : 53 - 59
  • [40] SLEEP DISTURBANCE IN PATIENTS WITH CIRRHOSIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT
    Zhao, Ming
    Luo, Xuefeng
    Wang, Xiaoze
    Yan, Yuling
    HEPATOLOGY, 2023, 78 : S1411 - S1411